Janus Henderson Global Life Sciences Fund S (JFNSX)
60.14
-1.62
(-2.62%)
USD |
May 13 2025
Key Stats
Customize
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.18% | 4.655B | 1.14% | 35.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -487.49M | -8.87% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term growth of capital. The Fund invests, under normal circumstances, at least 80% of its net assets in securities of companies that the portfolio managers believe have a life science orientation. The Fund normally invests in issuers from several different countries, which may include United States. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Janus Henderson Investors |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
90
-601.72M
Peer Group Low
1.261M
Peer Group High
1 Year
% Rank:
90
-487.49M
-5.812B
Peer Group Low
79.00M
Peer Group High
3 Months
% Rank:
90
-1.623B
Peer Group Low
129.85M
Peer Group High
3 Years
% Rank:
90
-12.56B
Peer Group Low
164.87M
Peer Group High
6 Months
% Rank:
90
-3.907B
Peer Group Low
22.73M
Peer Group High
5 Years
% Rank:
90
-20.03B
Peer Group Low
703.21M
Peer Group High
YTD
% Rank:
90
-2.403B
Peer Group Low
72.21M
Peer Group High
10 Years
% Rank:
90
-37.52B
Peer Group Low
615.98M
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of May 14, 2025.
Asset Allocation
As of December 31, 2024.
| Type | % Net |
|---|---|
| Cash | 0.00% |
| Stock | 99.43% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.21% |
| Other | 0.36% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly and Co | 9.39% | 715.65 | -4.08% |
| UnitedHealth Group Inc | 6.87% | 308.10 | -1.05% |
| AstraZeneca PLC | 4.01% | 135.36 | 0.00% |
| Johnson & Johnson | 3.59% | 146.16 | -1.54% |
| Boston Scientific Corp | 3.13% | 102.93 | -0.02% |
| Abbott Laboratories | 3.09% | 128.48 | -0.44% |
| Sanofi SA | 3.05% | 102.43 | -3.30% |
| Amgen Inc | 2.89% | 262.22 | -3.04% |
| AbbVie Inc | 2.82% | 177.07 | -5.81% |
| Vertex Pharmaceuticals Inc | 2.81% | 420.86 | -2.58% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 0.25% |
| Actual Management Fee | 0.64% |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 2500.00 None |
| Minimum Subsequent Investment | 0.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term growth of capital. The Fund invests, under normal circumstances, at least 80% of its net assets in securities of companies that the portfolio managers believe have a life science orientation. The Fund normally invests in issuers from several different countries, which may include United States. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Janus Henderson Investors |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (5-13-25) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Stock | |
| Weighted Average PE Ratio | 39.11 |
| Weighted Average Price to Sales Ratio | 10.31 |
| Weighted Average Price to Book Ratio | 9.410 |
| Weighted Median ROE | 11.83% |
| Weighted Median ROA | -2.98% |
| ROI (TTM) | -1.25% |
| Return on Investment (TTM) | -1.25% |
| Earning Yield | 0.0308 |
| LT Debt / Shareholders Equity | 1.694 |
As of December 31, 2024
Growth Metrics
| EPS Growth (1Y) | 10.70% |
| EPS Growth (3Y) | 4.61% |
| EPS Growth (5Y) | 9.67% |
| Sales Growth (1Y) | 14.75% |
| Sales Growth (3Y) | 16.77% |
| Sales Growth (5Y) | 16.51% |
| Sales per Share Growth (1Y) | 21.11% |
| Sales per Share Growth (3Y) | 20.24% |
| Operating Cash Flow - Growth Ratge (3Y) | 6.63% |
As of December 31, 2024
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:JFNSX", "name") |
| Broad Asset Class: =YCI("M:JFNSX", "broad_asset_class") |
| Broad Category: =YCI("M:JFNSX", "broad_category_group") |
| Prospectus Objective: =YCI("M:JFNSX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |